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iagnostic and Treatment of Snake Bites
. Franca
Vital Brazil Hospital in Butantan Institute, Sao Paulo, Brazil
Snake bites are very common in many rural areas of
frica, Asia and Latin America. The victims, in general,
re young adult males bitten during agricultural activities.
nake bites envenoming is one of the major neglected dis-
ases of the 21st century. The data about the morbidity and
ortality are limited but it’s estimated, globally, at least
21,000 envenoming and 20,000 deaths each year and also
hat almost 1.2 million to 5.5 million snake bites could occur
nnually. The snakes related with the most severe cases of
nake bite envenoming belong to Elapidae (cobras, kraits,
ambas, Australasian species and sea snakes) and Viperi-
ae (rattlesnakes, lance-headed pit vipers and true vipers)
amilies. The families Atractaspididae and Colubridae are
esponsible for a small fraction of the snake bites with med-
cal importance in Africa, Middle East and Central Asia. The
enus Echis sp. (saw-scaled vipers) in northern Africa, Naja
p. (cobras) and Bungarus sp. (kraits) in Asia and Bothrops
p. in Latin America are responsible for signiﬁcant numbers
f severe cases and deaths. The snake venoms are a com-
lex mixture of many families of toxins as haemorrhagins,
eurotoxins, serinoproteases, phospolipases, myotoxins and
thers. The most frequent emergencies in snake bites are
aused or a consequence a result of clotting and bleed-
ng disturbances, rhabdomyolisis, intravascular haemolysis,
uscle paralysis, local and systemic acute inﬂammation and
onsequent complications like severe hemorrhage, acute
enal failure, acute respiratory failure, hypotension and
hock, septicemia and severe local complications as com-
artmental syndrome, necrosis and amputation. The correct
uantity of speciﬁc antivenom by the intravenous route, as
oon as possible and supportive treatment are essential. The
ain challenges to control snake bites accidents are the pro-
uction and large distribution of high quality antivenoms and
xtensive and systematic training of the health care workers
bout diagnosis and treatment of snake bites.
oi:10.1016/j.ijid.2010.02.1500
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mmunobiologicals in South America
. MurilloUniversity of Miami, Miami, FL; USA
No Abstract Received.
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he Discovery of HIV
. Barre-Sinoussi
Institut Pasteur, Paris, France
Edward H. Kass Lecture
Soon after, the ﬁrst report of AIDS in the United States in
981, similar cases were observed in France. In December
982, a working group of clinicians contacted retrovirolo-
ists at the Institut Pasteur to work on the hypothesis that a
etrovirus might be the cause of AIDS. Together, they deﬁne
successful strategy to isolate HIV from a patient at risk of
IDS. This discovery was the start of a collective adventure,
hich mobilized clinicians, multidisciplinary researchers
nd patients, altogether. Such a networking turned out to be
ery efﬁcient for providing scientiﬁc evidences and for trans-
ating them rapidly into diagnosis, prevention and treatment
f HIV infection. Since these early days, we have learnt that
IV infection is much more complex than initially thought.
e have gained signiﬁcant insights into the HIV biology
nd pathogenesis. Early virologic and immunologic events,
articularly at mucosal sites, including the early virus dis-
emination, the establishment of viral reservoirs and the
ery rapid immune dysfunctions are critical in both HIV
cquisition and/or disease progression.
Despite all the enormous progress made during the last 27
ears at international level, HIV/AIDS epidemic still there.
esearch priorities still remain care, treatment and preven-
ion. One of the major scientiﬁc challenges is to develop
n efﬁcient HIV/AIDS vaccine. Conventional immunization
trategies may not be sufﬁcient to elicit protection. We
learly need to elucidate the precise mechanisms that are
overning the induction of protective immunity against HIV,
aking into consideration the most recent advances in innate
mmunity and insights on early innate effectors that HIV
an alter, including at mucosal sites. Lessons learned from
istinct models of protection in human and non-human pri-
ates and new approaches, including systems biology will
ertainly contribute to novel concepts for future HIV vaccine
esearch and development.
oi:10.1016/j.ijid.2010.02.1502
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nducible Dormant MRSA
. Bearman1,∗, A. Rosato2, K. Elam2, M. Edmond3
Richmond, VA, USA
Virginia Commonwealth University, Richmond, Va, USA
Medical College of Virginia Campus, Richmond, VA, USA
Inducible Dormant (ID) MRSA are mecA gene-positive
.aureus isolates that change from initial MSSA phenotype
o CA-MRSA phenotype after !-lactam antibiotic exposure
They can be identiﬁed by SCC mec type. ID-MRSA has been
eported in both hospital and community settings.
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In healthcare facilities, transmission of ID-MRSA from
a HCW to a patient has been postulated. In an earlier
report, a HCWwas colonized with MRSA after treatment with
cephalexin. Exposure to the antibiotic was the purported
inducer of phenotypic resistance. Until recently, there have
been no prior epidemiological reports of ID-MRSA in the non-
healthcare setting. A prospective epidemiologic surveillance
study identiﬁed ID MRSA in a cohort of healthy university
students. The potential impact of ID-MRSA colonization on
CA-MRSA colonization and subsequent development of skin
and soft tissue infections or invasive disease is not known.
As in the hospital setting, ID-MRSA colonization may serve
as a reservoir, thereby promoting cross-transmission within
a household, dormitory, athletic team or social unit. Colo-
nized individuals may theoretically cross transmit ID-MRSA
isolates to close contacts. Additionally, ID-MRSA colonization
or transmission may result in MRSA phenotypic conversion if
the appropriate selective antibiotic pressure is applied. Fur-
thermore, individuals persistently colonized with ID-MRSA
may play an important role in households with high rates
of CA-MRSA infections. Further studies are needed to better
deﬁne both mechanisms of resistance and the epidemiologic
signiﬁcance of ID-MRSA.
doi:10.1016/j.ijid.2010.02.1503
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The Role of PVL in Severe Disease - What is the Evidence?
K. Christiansen
Royal Perth Hospital, Perth, Australia
ST8-MRSA-IV (USA300), ST80-MRSA-IV (European clone),
ST59-MRSA-IV (Taiwan clone) and in Australia ST93-MRSA-
IV (Queensland clone) and ST30-MRSA-IV (Oceania clone)
are all PVL positive. Data from Australia where CA-MRSA
has been described since the late 1980’s show that disease
severity and demographics vary widely between PVL positive
and negative clones.
Demonstrating the actual role of PVL in disease has been
controversial. Mouse and rat animal models using PVL pos-
itive and negative clones or PVL deleted mutants have
provided some support for a role in muscle damage, skin
abscess and lung necrosis but there are studies that fail
to show any association of PVL with pathogenesis of CA-
MRSA disease. In contrast rabbit models have demonstrated
a role in lung necrosis, dermatonecrosis and osteomyelitis
- a reﬂection of the greater sensitivity of rabbit polymor-
phonuclear (PMN) leucocytes to PVL than murine PMNs.
As with most biological systems one single factor is rarely
the explanation for a complex disease. Other virulence
factors have been described for CA-MRSA including core
genomic factors such as alpha haemolysin, secreted pro-
teases, phenol-soluble modulins (PSMs), increased expres-
sion of the accessory gene regulator (agr) and especially for
USA300 the possession of the arginine catabolic mobile ele-
ment (ACME) that has a role in pH homeostasis, ﬁtness and
possibly transmission. More recently PSMs that are associ-
ated with the SCCmec have been described.
Conclusion: PVL is not necessarily a driver of the CA-
MRSA epidemics being seen worldwide but is more likely a
determinant of signiﬁcant skin and soft tissue infection with
3
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bscess formation as well as more severe disease such as
ecrotising pneumonia, necrotising fasciitis and osteomyeli-
is.
oi:10.1016/j.ijid.2010.02.1504
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RSA Control Programs in the UK: Impact on Quality of
are, Nosocomial Infection, and Public Perception
. Gould
Royal Inﬁrmary, Aberdeen, Saudi Arabia
Driven largely by public and hence political pressure,
he NHS has made good progress in reducing MRSA bacter-
emia. By the end of June 2009, they had fallen to 26%
f 2003-04 levels in England and Wales. Little data how-
ver, is available on background MRSA colonisation rates or
ther types of infection although HAI audits suggest MRSA
s still the dominant cause of postoperative wound infec-
ion. Signiﬁant resource is now being invested in universal
dmission screening and early signs are that this is being
uccessful with signigicant reduction in colonization rate
t admission, overall burden on isolations rooms, clincially
iagnosed infections and laboratory clinical isolates. The
ittle evidence available suggests that the public is happy
ith screening programmes. Nevertheless, signiﬁcant con-
erns remain at public health level about the use of these
esources for MRSA screening and at an ethical level about
he enforced isolations of patients with possible detrimental
ffects on quality of care.
oi:10.1016/j.ijid.2010.02.1505
0.004
RSA epidemiology and Control in Developing Countries
. Rosenthal
International Nosocomial Infection Control Consortium
INICC), Buenos Aires, Argentina
International infection control consortium (INICC)
eported data from January 2003 through December 2008
n 173 ICUs in Latin America, Asia, Africa, and Europe.
uring the 6-year study, using CDC NNIS/NHSN deﬁnitions
or device-associated healthcare-associated infection, we
ollected prospective data from 155,358 patients hospital-
zed in the consortium’s hospital ICUs for an aggregate of
23,624 days.
Although device utilization in the developing countries’
CUs was remarkably similar to that reported from U.S.
CUs in the CDC’s NHSN, rates of device-associated noso-
omial infection were markedly higher in the ICUs of the
NICC hospitals: the pooled rate of CVC-associated BSI in
he INICC ICUs, 7.6 per 1000 CVC days, is nearly three-
old higher than the 2.0 per 1000 CVC-days reported from
omparable U.S. ICUs, and the overall rate of ventilator-
ssociated pneumonia (VAP) was also far higher, 13.6 vs
.3 per 1000 ventilator-days, as was the rate of catheter-
ssociated urinary tract infection (CAUTI), 6.3 vs. 3.3 per
000 catheter-days.
